• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Use of a Novel Negative-Pressure Tent During Bedside Tracheostomy in COVID-19 Patients
ConclusionsIt is feasible to perform PDT on intubated COVID-19 patients using the AerosolVE negative-pressure tent. This is a promising low-cost device to decrease risk to healthcare providers during AGPs.
Source: Neurocritical Care - August 6, 2020 Category: Neurology Source Type: research

Portable fibrobronchoscopic treatment for non-severe ischemic stroke-associated pneumonia patients with dysphagia: a pilot study.
CONCLUSION: Sputum suction and alveolar lavage with portable fibrobronchoscope can significantly improve the hypoxia and pulmonary infections, reduce the inflammatory response, and thus improve the prognosis, rendering suction and alveolar lavage with portable fibrobronchoscope as a safe and effective treatment for non-severe ischemic SAP patients with dysphagia. PMID: 30657017 [PubMed - as supplied by publisher]
Source: Neurological Research - January 19, 2019 Category: Neurology Tags: Neurol Res Source Type: research

Effect evaluation on use of bedside fiber bronchoscope in treating stroke-associated pneumonia.
Conclusion The use of bedside fiber bronchoscope is beneficial in modifying the pulmonary ventilation and relieving systemic inflammatory response of patients with SAP, exhibiting a great value in clinical application. PMID: 29785872 [PubMed - as supplied by publisher]
Source: Topics in Stroke Rehabilitation - May 22, 2018 Category: Neurology Authors: Han Q, Chen C, Hu HQ, Shen J, Yang G, Chen B, Xia L Tags: Top Stroke Rehabil Source Type: research

Right Hemispheric Acute Ischemic Stroke Secondary To Right Common Carotid Artery Free Floating Thrombus Due To Hypercoagulable State In An Otherwise Healthy 48-Year-Old Woman. (P6.263)
Conclusions: Due to the high association between malignancy and hypercoagulable state, further work up needs to be warranted in the evaluation of a patient with FFT. To our knowledge this is the first case report of symptomatic FFT treated with an oral direct factor-Xa inhibitor. Further randomized clinical trials are required to assess the best therapeutic approach of this condition.Disclosure: Dr. Orjuela has nothing to disclose. Dr. Gill has nothing to disclose. Dr. Vlahovic has nothing to disclose. Dr. Morales-Vidal has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Orjuela, K., Gill, R., Vlahovic, L., Morales-Vidal, S. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research